1 Min Read
Feb 14 (Reuters) - The U.S. Food and Drug Administration:
* SAYS APPROVED JANSSEN PHARMACEUTICAL’S ERLEADA FOR A CERTAIN TYPE OF PROSTATE CANCER USING NOVEL CLINICAL TRIAL ENDPOINT Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.